AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11359590 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 4: Detection of an audible noise by neck stethoscopy
Number of subjects: 80
Study 9251160 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 mg)
Number of subjects: 30
Study 9251160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7506335 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide
Number of subjects: 0
Study 3030581 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg)
Number of subjects: 12
Study 3030581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30574860 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral bovine lactoferrin (150 mg/kg/day; maximum 300 mg/day)
Number of subjects: 2203
Study 30574860 — intervention group
Group type: COMPARATOR
Intervention: Sucrose placebo (same dose)
Number of subjects: 2203
Study 30574860 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral bovine lactoferrin
Number of subjects: 2203
Study 30574860 — intervention group
Group type: COMPARATOR
Intervention: Sucrose placebo
Number of subjects: 2203
Study 26522861 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-layer closure with unlocked first layer
Number of subjects: 81
Study 26522861 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-layer closure with locked first layer
Number of subjects: 81
Study 26522861 — intervention group
Group type: COMPARATOR
Intervention: Single-layer closure
Number of subjects: 81
Study 25843533 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum (CCH) 0.58 mg/0.20 mL injected into palpable cord
Number of subjects: 506
Study 25843533 — intervention group
Group type: COMPARATOR
Intervention: Placebo (only in Collagenase Option for Reduction of Dupuytren I/II)
Number of subjects: 506
Study 23630033 — intervention group
Group type: EXPERIMENTAL
Intervention: LX4211
Number of subjects: 0
Study 23630033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21030144 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 80mg daily for 3 months
Number of subjects: 31
Study 21030144 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 31
Study 20126853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone every three weeks (HR group)
Number of subjects: 62
Study 20126853 — intervention group
Group type: COMPARATOR
Intervention: Oral vitamins daily (HV and CV groups)
Number of subjects: 62
Study 18046974 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril 30 mg od (up-titrated to 60 mg od after 4 weeks in non-responders)
Number of subjects: 0
Study 18046974 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg od (up-titrated to 40 mg od after 4 weeks in non-responders)
Number of subjects: 0
Study 18046974 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril
Number of subjects: 0
Study 18046974 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0
Study 14762880 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoirradiation with cisplatin 100 mg/m2 on days 1, 22, and 43 of radiotherapy, followed by adjuvant chemotherapy with ifosfamide 1.4 g/m2, 5-fluorouracil 450 mg/m2, and leucovorin 20 mg/m2 daily for 5 days, repeated every 3 weeks for three cycles
Number of subjects: 35
Study 14762880 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy
Number of subjects: 35
Study 14762880 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoirradiation with cisplatin
Number of subjects: 35
Study 14762880 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy
Number of subjects: 35
Study 14762880 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 35
Study 14762880 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent and adjuvant chemotherapy
Number of subjects: 35
Study 11683693 — intervention group
Group type: EXPERIMENTAL
Intervention: OAAz (amoxicillin 1000 mg b.d. and azithromycin 500 mg on day 1 and 250 mg on days 2-5)
Number of subjects: 323
Study 11683693 — intervention group
Group type: EXPERIMENTAL
Intervention: OCM (clarithromycin 250 mg b.d. and metronidazole 500 mg b.d.)
Number of subjects: 323
Study 11683693 — intervention group
Group type: EXPERIMENTAL
Intervention: OBC (bacampicillin 1200 mg b.d. and clarithromycin 500 mg b.d.)
Number of subjects: 323
Study 11683693 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC (omeprazole 20 mg b.d., amoxicillin 1000 mg b.d., and clarithromycin 500 mg b.d.)
Number of subjects: 323
Study 9215782 — intervention group
Group type: COMPARATOR
Intervention: Accelerated hyperfractionation (AHF) - 0.89 Gy x 3 fractions/day; total dose 61.4 Gy
Number of subjects: 0
Study 9215782 — intervention group
Group type: COMPARATOR
Intervention: Accelerated fractionation (AF) RT
Number of subjects: 0
Study 9215782 — intervention group
Group type: COMPARATOR
Intervention: Hyperfractionation (HF)
Number of subjects: 0
Study 9215782 — intervention group
Group type: COMPARATOR
Intervention: Non-conventional fractionation (non-CF) RT
Number of subjects: 0
Study 7782974 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (CCL) for 1 week
Number of subjects: 62
Study 7782974 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (CCL) for 2 weeks
Number of subjects: 62
Study 7782974 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (CFIX) for 1 week
Number of subjects: 62
Study 7782974 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (CFIX) for 2 weeks
Number of subjects: 62
Study 2168123 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat-bran cereal diet (25 g oat bran/d)
Number of subjects: 12
Study 2168123 — intervention group
Group type: COMPARATOR
Intervention: Corn flakes diet (control)
Number of subjects: 12
Study 704919 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-Methyl 16,16 Dimethyl Prostaglandin E2 (TM-PGE) administered orally at dosages of 2.5, 5, 7.5, and 10 microgram/kg
Number of subjects: 0
Study 704919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31314952 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve Growth Factor (NGF) injections (1 µg, 4 cm interval)
Number of subjects: 21
Study 31314952 — intervention group
Group type: COMPARATOR
Intervention: Control injections (isotonic-saline)
Number of subjects: 21
Study 28716283 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalfampridine extended release (D-ER) 10mg tablets twice daily
Number of subjects: 22
Study 26154829 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (six education sessions over 3 weeks)
Number of subjects: 160
Study 26154829 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 160
Study 25533024 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapropterin therapy
Number of subjects: 206
Study 25533024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 23990508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligasure™ LF1212
Number of subjects: 245
Study 23990508 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic FOCUS(®)
Number of subjects: 245
Study 20485256 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopic surveillance with random and targeted biopsies
Number of subjects: 0
Study 20485256 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel endoscopic techniques (conventional or virtual chromoendoscopy, confocal laser endomicroscopy)
Number of subjects: 0
Study 20485256 — intervention group
Group type: COMPARATOR
Intervention: Current surveillance strategies based on disease duration
Number of subjects: 0
Study 18254805 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment based on silymarin/methylsulfonylmethane (S‐MSM) for 1 month
Number of subjects: 46
Study 18254805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 16487480 — intervention group
Group type: EXPERIMENTAL
Intervention: High mood induction in euthymic bipolar I disorder group
Number of subjects: 96
Study 16487480 — intervention group
Group type: EXPERIMENTAL
Intervention: Low mood induction in euthymic bipolar I disorder group
Number of subjects: 96
Study 16487480 — intervention group
Group type: COMPARATOR
Intervention: High mood induction in remitted unipolar group
Number of subjects: 96
Study 16487480 — intervention group
Group type: COMPARATOR
Intervention: Low mood induction in remitted unipolar group
Number of subjects: 96
Study 16487480 — intervention group
Group type: COMPARATOR
Intervention: High mood induction in never-depressed healthy controls
Number of subjects: 96
Study 16487480 — intervention group
Group type: COMPARATOR
Intervention: Low mood induction in never-depressed healthy controls
Number of subjects: 96
Study 12581050 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-enhanced spiral CT (NECT)
Number of subjects: 200
Study 12581050 — intervention group
Group type: COMPARATOR
Intervention: Intravenous pyelography (IVP)
Number of subjects: 200
Study 12581050 — intervention group
Group type: EXPERIMENTAL
Intervention: Both NECT and IVP
Number of subjects: 200
Study 10807760 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ethinyl estradiol plus cyproterone acetate (CA)
Number of subjects: 30
Study 10807760 — intervention group
Group type: COMPARATOR
Intervention: Transdermal 17beta-estradiol plus CA
Number of subjects: 30
Study 10807760 — intervention group
Group type: COMPARATOR
Intervention: Oral CA alone
Number of subjects: 30
Study 10807760 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular testosterone esters in transsexual females
Number of subjects: 30
Study 10807760 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ethinyl estradiol plus CA
Number of subjects: 30
Study 10807760 — intervention group
Group type: COMPARATOR
Intervention: Parenteral testosterone in females
Number of subjects: 30
Study 9500129 — intervention group
Group type: EXPERIMENTAL
Intervention: Somnium (lorazepam 1 mg + diphenhydramine 25 mg)
Number of subjects: 44
Study 9500129 — intervention group
Group type: COMPARATOR
Intervention: lorazepam (1 mg)
Number of subjects: 44
Study 8198304 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital block
Number of subjects: 30
Study 8198304 — intervention group
Group type: COMPARATOR
Intervention: Metacarpal block
Number of subjects: 30
Study 3286733 — intervention group
Group type: EXPERIMENTAL
Intervention: Food allergy
Number of subjects: 140
Study 28947180 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24IU)
Number of subjects: 19
Study 28947180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 27846888 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary fixation
Number of subjects: 198
Study 27846888 — intervention group
Group type: COMPARATOR
Intervention: Extramedullary fixation
Number of subjects: 198
Study 25707702 — intervention group
Group type: EXPERIMENTAL
Intervention: Central pathology review of prostatic biopsies
Number of subjects: 642
Study 22939991 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 28
Study 22939991 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 28
Study 20587669 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple intervention (prompt letter from the MCO medical director)
Number of subjects: 2357
Study 20587669 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise intervention (prompt letter from MCO, second letter from primary care physician, counseling from lay health workers)
Number of subjects: 2357
Study 20587669 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 2357
Study 18371557 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC-guided strategy
Number of subjects: 194
Study 18371557 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment alone
Number of subjects: 194
Study 16368472 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional HRT (estradiol (E2) 2 mg/d during 12 days, E2 2 mg/d plus 1 mg/d of norethisterone acetate (NETA) during 10 days, E2 1 mg/d for 6 days)
Number of subjects: 73
Study 16368472 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-cycle HRT (two cycles with E2 2 mg/d during 28 days, followed by one cycle of conventional HRT and repeated every 3 months)
Number of subjects: 73
Study 16368472 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 73
Study 12830471 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin monotherapy (1,000 mg daily, adapted to hemoglobin level)
Number of subjects: 48
Study 12830471 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ribavirin therapy)
Number of subjects: 48
Study 10953765 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg scopolamine
Number of subjects: 22
Study 10953765 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg scopolamine
Number of subjects: 22
Study 10953765 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mg scopolamine
Number of subjects: 22
Study 10953765 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg subcutaneous physostigmine
Number of subjects: 22
Study 10953765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 8998818 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulfone (PS) membrane
Number of subjects: 9
Study 8998818 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose diacetate (CDA) membrane
Number of subjects: 9
Study 7890463 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced Volume Taper (RVT)
Number of subjects: 8
Study 7890463 — intervention group
Group type: COMPARATOR
Intervention: Rest Only Taper (ROT)
Number of subjects: 8
Study 2953994 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic vibration reflex (TVR)
Number of subjects: 0
Study 2953994 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger flexion reflex
Number of subjects: 0
Study 29229613 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture alone
Number of subjects: 224
Study 29229613 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus auricular acupuncture (combination treatment)
Number of subjects: 224
Study 29229613 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 224
Study 26998845 — intervention group
Group type: COMPARATOR
Intervention: Primary debulking surgery (PDS) followed by systemic adjuvant chemotherapy (arm A)
Number of subjects: 110
Study 26998845 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by interval debulking surgery (NACT/IDS) (arm B)
Number of subjects: 110
Study 24363029 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 160/80 (160 mg at weeks 0/2, then 40 mg every other week)
Number of subjects: 273
Study 24363029 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 160/80
Number of subjects: 273
Study 24363029 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 273
Study 24363029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study 23027232 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise identity (EXID) and attributional property of controllability
Number of subjects: 224
Study 20007996 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim (FIL) at a daily dose of 5 mug/kg
Number of subjects: 80
Study 20007996 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (PEG) at a single fixed dose of 6 mg
Number of subjects: 80
Study 20007996 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim (FIL)
Number of subjects: 80
Study 20007996 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (PEG)
Number of subjects: 80
Study 17180356 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial cervical disc replacement
Number of subjects: 24
Study 17180356 — intervention group
Group type: COMPARATOR
Intervention: Interbody fusion
Number of subjects: 24
Study 16756652 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 9 schools) with two additional physical education classes per week, short PA breaks during lessons, PA homework, and adaptation of recreational areas.
Number of subjects: 15
Study 12537034 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 19
Study 12537034 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 19
Study 10799425 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (500 mg daily for nine weeks)
Number of subjects: 10
Study 10799425 — intervention group
Group type: COMPARATOR
Intervention: Control group (FO unsupplemented children)
Number of subjects: 10
Study 10799425 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation
Number of subjects: 10
Study 9735591 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry heat exposure (Gr A, N = 5) at 41.3 +/- 0.6 degrees C DB, 40-50% RH
Number of subjects: 11
Study 9735591 — intervention group
Group type: EXPERIMENTAL
Intervention: Humid heat exposure (Gr B, N = 6) at 39.2 +/- 0.6 degrees C DB, 70-80% RH
Number of subjects: 11
Study 1640192 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline + Metoprolol
Number of subjects: 24
Study 1640192 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 24
Study 1640192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1640192 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 24
Study 1640192 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline + Placebo
Number of subjects: 24
Study 1640192 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol + Placebo
Number of subjects: 24
Study 1640192 — intervention group
Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 24
Study 6667282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6667282 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockade (propanolol 160 mg/day)
Number of subjects: 16
Study 31305878 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media use
Number of subjects: 3826
Study 31305878 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer use
Number of subjects: 3826
Study 31305878 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media use (within-person association)
Number of subjects: 3826
Study 31305878 — intervention group
Group type: EXPERIMENTAL
Intervention: Television use (within-person association)
Number of subjects: 3826
Study 29642136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical Disc Replacement (CDR)
Number of subjects: 253
Study 29642136 — intervention group
Group type: COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion (ACDF)
Number of subjects: 253
Study 26732683 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (15 mg/kg)
Number of subjects: 124
Study 26732683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 25326927 — intervention group
Group type: EXPERIMENTAL
Intervention: ART
Number of subjects: 367
Study 25326927 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient care
Number of subjects: 367
Study 25326927 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient care
Number of subjects: 367
Study 25326927 — intervention group
Group type: EXPERIMENTAL
Intervention: Other medications
Number of subjects: 367
Study 22269152 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg plus Fenofibrate 160 mg
Number of subjects: 180
Study 22269152 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg
Number of subjects: 180
Study 20303247 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg plus qd salmeterol 50 microg
Number of subjects: 95
Study 20303247 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg plus bid salmeterol 50 microg
Number of subjects: 95
Study 20303247 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium or salmeterol alone
Number of subjects: 95
Study 20303247 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies including salmeterol qd or bid
Number of subjects: 95
Study 17710485 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of prednisolone intravenously for 3 days (steroid group)
Number of subjects: 31
Study 17710485 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prednisolone)
Number of subjects: 31
Study 15837772 — intervention group
Group type: EXPERIMENTAL
Intervention: Racol (RAC) formula rich in omega-3 PUFAs
Number of subjects: 28
Study 15837772 — intervention group
Group type: COMPARATOR
Intervention: Ensure Liquid (control)
Number of subjects: 28
Study 11949746 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction (no water seal)
Number of subjects: 52
Study 11949746 — intervention group
Group type: COMPARATOR
Intervention: Water seal
Number of subjects: 52
Study 9452942 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (up to 10 mg/day)
Number of subjects: 133
Study 8578163 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (60 mg every morning for 14 days) + Amoxicillin (500 mg oral suspension four times daily for 11 days)
Number of subjects: 65
Study 8578163 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (60 mg every morning for 14 days)
Number of subjects: 65
Study 8578163 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-negative patients
Number of subjects: 65
Study 8578163 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-positive patients
Number of subjects: 65
Study 8578163 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole + Amoxicillin
Number of subjects: 65
Study 2804254 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin in Vehicle‐N (Neutrogena)
Number of subjects: 12
Study 2804254 — intervention group
Group type: COMPARATOR
Intervention: Cleocin‐T
Number of subjects: 12
Study 349673 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-containing chewing gum
Number of subjects: 20
Study 349673 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 20
Study 31768768 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfocused extracorporeal shockwave therapy (3,000 electrohydraulic-generated shockwaves at 0.3 mJ/mm2)
Number of subjects: 12
Study 31768768 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral forearm)
Number of subjects: 12